Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are becoming increasingly popular for the treatment of type II diabetes and obesity. Body mass index (BMI) thresholds at in vitro fertilization (IVF) clinics may further drive the use of these medications before infertility treatment. ...
Glucagon-like peptide-1 (GLP-1) has been the focus of considerable research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incretin effect is significantly reduced or absent in individuals with T2DM. Thus, pharmacologic efforts to develop medications that mimic the actions...
Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications Glucagon-like peptide-1 (GLP-1) has been the focus of considerable research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incret... JR Unger,CG Parkin - 《Diabetes Therapy》 被...
Glucagon-like peptide 1 (GLP-1) agonists are medications approved for treatment of diabetes that recently have also been used off label for weight loss.1Studies have found increased risks of gastrointestinal adverse events (biliary disease,2pancreatitis,3bowel obstruction,4and gastroparesis5) in patie...
The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts w
The unique glycine residue at the DPP-IV cleavage site renders the protein unrecognizable by DPP-IV and prolongs the half-life of the peptide. Thus, the exendin-4 backbone has been utilized in the creation of longer-acting synthetic GLP-1R agonists.Figure adapted from Glotfelty et al. [5]....
glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits. Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in...
glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of antidiabetic drugs noted not only for their potent glucose-lowering effects but also for their cardiovascular and renal protective benefits. Various GLP-1RAs have been demonstrated to have significant benefits in in vitro and in...
Glucagon-like peptide (GLP)-1 receptor agonists have revolutionized the treatment of patients withtype 2 diabetes mellitusand obesity. These medications stimulate glucose-dependentinsulin releasefrom the pancreas, slow gastric emptying, and inhibit postmealglucagon release, which lead to...